Moreover, we successfully detected T-cell response to small and large tumors, including autochthonous liver tumors. The adoptively transferred T cells were not ignorant or excluded in a partially tolerant host, which expressed low level of the target in the periphery. Using T cell receptor-engineered T cells, we showed the ability of these cells to respond in tumorbearing hosts by expanding and homing to the tumor site. In all these models, the host immune status, the nature of the tumor or of the antigen, the tumor size, and the presence of the targeted antigen in the periphery did not prevent the adoptively transferred T cells from responding by expanding and homing to the tumor. However, T cells had higher expression of the inhibitory receptor PD1 and reduced functional activity when a self-antigen was targeted.
Novelty and impact
The ability of adoptively transferred T cells to expand, and home to tumors are essential steps for successful therapy. Using mouse models that differed in tumor burden, nature of targeted antigen and tumor location, we found that neither ignorance nor immunological exclusion prevented the in vivo response of transferred T cells. In contrast, functionally active T cells with low expression of the inhibitory receptor PD1 were mainly observed in the immunodeficient and target-antigen-negative tumor-bearing hosts.
Introduction
Adoptive T-cell therapy is currently used in the clinic to treat malignancies [1] [2] [3] [4] [5] [6] [7] . However, limited expansion, poor trafficking, and little accumulation of adoptively transferred T cells at the tumor site were suggested to constrain successful therapy. Using murine xenograft models, it has been demonstrated that enhanced trafficking of transferred T cells to the tumors can be obtained if appropriate chemokine's receptors were introduced to these T cells [8] [9] [10] . However, whether syngeneic tumors, including autochthonous tumors, are ignored or can be sufficiently detected in vivo using adoptively transferred T cells need to be evaluated.
Different imaging techniques are available to detect cells in live mice with variable sensitivities and resolutions 11 . BLI measures the emitted photons resulting from the enzymatic activity of a luciferase upon injection of its substrate. BLI is safer and more suitable than other small animal imaging techniques when mice are to be imaged repeatedly [11] [12] [13] . BLI is sensitive and basically background free because mouse tissues do not produce detectable light 13, 14 . Different cell populations expressing different luciferases can be imaged simultaneously and discriminated based on their substrate utilization and the wavelength of the emitted light 15 . Furthermore, the acquisition time for BLI is short and up to 5 mice can be imaged in parallel, thus making BLI a high throughput in vivo imaging technique.
In the field of cancer immunology, BLI is used to monitor tumor growth following ectopic luciferase expression in tumor cell lines. This technique is highly sensitive, enabling the detection of as few as 1000 tumor cells expressing FLuc 16 and 1000 T cells expressing RLuc 17 . Interestingly, a clear linear correlation exists between the cell number and the imaged signal of T cells obtained from the RLuc mice 17 . Recently, transgenic mouse models were established in which expression of a luciferase is linked to the oncogene indirectly by controlled co-expression or directly as a fusion protein [18] [19] [20] [21] [22] .
T cells are among the most sensitive cells of the immune system with their ability to detect trace amount of antigen 23 . Others and we showed that adoptively transferred antigen-specific T cells can be detected in the transplanted tumor 17, [24] [25] [26] [27] [28] . After injecting T cells expressing RLuc (RLuc-T), a strong T cell signal can be measured specifically from the target tumor site.
Recently, more sophisticated and physiologically relevant mouse models were developed which include genetically induced or sporadic tumor mouse models. In these models, the oncogene is a self-antigen expressed at low level on healthy tissues, rendering these mice fully or partially tolerant toward the oncogene [18] [19] [20] [21] [22] [29] [30] [31] [32] [33] [34] [35] . Adoptively transferred T cells failed to control tumor growth in these autochthonous, self-antigen induced tumor models 19 . To evaluate whether immune exclusion mechanisms in these mice prevented the T cell response 36 , we established an approach that we termed RT-Rack, for in vivo RLuc T cell tracking, combining the high sensitivity of T cells for their target antigen with the high sensitivity of BLI. We applied RT-Rack in various tumor-bearing mouse models, including mice with autochthonous tumors overexpressing a model self-antigen, to evaluate the capacity of adoptively transferred T cells to survive, recognize syngeneic tumor-derived antigens, expand, and traffic to tumor site in vivo. . LTL mice were challenged s.c. with 3-10x 6 9.27P cells. LTL x Alb-Cre mice developing autochthonous HCC were described earlier 19, 31 .
Materials and Methods

Cells
Tumor mean diameter was measured along three orthogonal axes (a, b and c) by a digital caliper and calculated as earlier described 39 . To be able to measure the smallest tumors in our study, tumor-injection-site was sprayed with 70% ethanol to enable the visualization of small palpable tumor nodules, which were then measured by electronic caliper. When no palpable tumor nodule was detected, similar procedures were followed using 70% ethanol spray to confirm the absence of a visible tumor nodule. Immunodeficient or immunosupressed mice (Rag -/-mice or mice with a large tumor burden) received antibiotic treatment. All mouse studies were carried out in accordance with institutional, state, and federal (Landesamt für Arbeitsschutz, Gesundheitsschutz und technische Sicherheit, Berlin) guidelines.
In vivo bioluminescence
Renilla luciferase (RLuc) activity was detected by retro-orbital (ro.) injection of 100 µl of coelenterazine at 1 mg/ml (Biosynth), dissolved in 30% DMSO (Sigma-Aldrich,), 70% PBS (MgCl 2 and CaCl 2 free (Invitrogen)), followed by direct measurement with the IVIS ® 200
Imaging System for 1 minute, using small binning. Firefly luciferase (FLuc) activity was detected by injecting intravenously 100 µl of D-luciferin at 30 mg/ml (Biosynth), dissolved in PBS. Measurement was taken for 1 to 60 seconds using small or medium bining. Data 
RLuc-OT-I T cell activation and treatment
Splenocytes from R-OT 17 transgenic mice were cultured in a 24-well plate at a concentration of 2x10 6 cells/ml in presence of 1 µg/ml anti-CD3 antibody (BD Biosciences), 0.1 µg/ml anit-CD28 antibody (BD Biosciences) and 1 µg/ml SIINFEKL peptide (Biosyntan) for 24 hours in complete RPMI medium (i.e. RPMI-1640 Glutamax-I supplemented with 50 µM β-mercaptoethanol, 0.1 µg/ml gentamicin (all from Invitrogen) and 10% FCS (Pan-Biotech)). 24 hours later, the medium was replaced with fresh medium containing 10 IU/ml IL-2 (interleukin-2 (Novartis)) for 3 days. 10x10 6 cells were then injected ro. (in 100 µl PBS) into EG.7F or EG.7F and EL-4F tumor-bearing B6/Albino mice.
ChRLuc-TCRI T cell activation and treatment
ChRLuc-TCRI 17 mice were immunized by intraperitoneal injection of 1x10 7 16.113 cells.
The spleens of these mice were harvested one week later and CD8 + T cells were purified by MACS using the CD8 negative isolation kit (Miltenyi µM β-mercaptoethanol, 0.1 µg/ml gentamicin (all from Invitrogen) and 10% FCS (PanBiotech)) were added and the cells were incubated overnight at 37°C. The medium was then replaced by fresh complete RPMI medium supplemented with 10 U/ml IL-2. Retroviruscontaining supernatants were harvested 24h and 48 hours later.
Retroviral transduction 1x10 6 cells/ml splenocytes from Rag-ChRLuc-OT-I mice 17 were activated in vitro in 24-well plates in complete RPMI medium supplemented with 1 µg/ml anti-CD3, 0.1 µg/ml anti-CD28
antibodies, 1 µg/ml SIINFEKL and 10 IU/ml IL-2. 24 hours later, the splenocytes were transduced by spinocculation. Briefly, 70% of the medium was replaced by 1 ml of retroviruscontaining supernatant supplemented with 10 µg/ml polybrene (Sigma) another was cryopreserved, while the third part was used to isolate Tumor-infiltrating lymphocytes (TILs) for flow cytometry analyses. Paraffin embedded sections were stained for H&E, SV40 Large T and FLuc, while CD8 staining was performed on cryosections. Staining was performed as previously described 19, 30, 31 .
Isolation of tumor-infiltrating lymphocytes
9.27P tumors were cut into small fragments and digested in 2-4 ml of PBS supplemented with 78.8 µg/ml Liberase TM (Roche) and 30 U/ml DNase I (Roche) for 30 minutes at 37°C, followed by 20 minutes at room temperature. The suspension was then forced through a 40 µm cell strainer and washed twice with PBS. The TILs were then separated from the cell suspension on ficoll gradient using Ficoll-Paque TM (GE).
In vitro stimulation of TILs and splenocytes
TILs (0.5x10 6 ) were cultured with naïve C57BL/6 splenocytes (2x10 6 ) in presence of 1 µg/ml peptide I of SV40 Large T or 1 µg/ml gp33 peptides (Genquest). Splenocytes (2x10 6 ) from tumor-bearing mice were cultured in presence of 1 µg/ml peptide I of SV40 Large T or 1 µg/ml gp33 peptides. All cultures were done in 24-well plate over night at 37°C, in 1 ml complete RPMI medium, supplemented with 1 µl/ml Golgi Plug (BD).
Flow cytometry of TILs and splenocytes
TILs and splenocytes were stained ex vivo for cell surface expression of CD8, Vβ7, CD44, 
Statistical analysis
Averages and standard deviations for light signals and flow cytometry values were calculated using Microsoft Excel 2007 (Microsoft Deutschland GmbH).
Results
T-cell expansion and homing are antigen dependent
We have shown earlier that T cell accumulation into large tumors is antigen specific and leads to the detection of a strong and reliable signal by BLI and confirmed the homing by flow 
RT-Rack detected response to large, medium, and small tumors and to unpalpable tumor cell mass
Having confirmed that RT-Rack can detect T-cell homing to antigen positive tumors, we evaluated the sensitivity of this approach by injecting RLuc-T cells into 4 groups of mice bearing decreasing EG.7F tumor burden or unpalpable EG.7F tumor cell mass.
At the day of T cell injection, tumor cells masses were either unpalpable or had a mean diameter of 1, 7 or 10 mm. This size difference correlated with the tumor specific FLuc signals (Fig. 1D) . Following the injection into the tumor bearing hosts, T cells expanded, homed, and accumulated in the antigen positive tumors within 3 to 4 days and remained there for 3 more days as shown by a stable T cell signal between days 3 and 6 after T cell injection (Fig. 1E ). The T cell signal then decreased, corresponding to the contraction phase of a normal immune response (Fig. 1E ). Despite the difference in the sizes of targeted tumors, R-OT T cells expanded and homed to all these tumors (Fig. 1F) , proving that RT-Rack is sensitive enough to detect T-cell response to small, and even unpalpable tumor cell masses in vivo. Fig. S1 , S2B, and S2D).
T cell expansion and homing was not limited by the host immune status
After evaluating RT-Rack with a model tumor antigen, we tested whether this approach could Fig. S2D-G) . Moreover, the kinetics of T cell accumulation was similar in Rag -/-and C57BL/6 mice, starting at day 3 and peaking at day 6 (Fig. 2C) . However, T cells proliferated more in Rag -/-mice, leading to higher signal from whole body (Fig. 2D ) and secondary lymphoid organs ( Fig. 2A-B ) from these mice compared to C57BL/6 mice. In addition to the signals detected from the tumor and presumably secondary lymphoid organs, a specific T-cell signal was measured from the lung of the immunodeficient mice (Fig. 2B) , most likely due to T cell accumulation at the site of metastatic lesions. This was confirmed by immunohistochemistry, following staining for Tag in the lung sections from mice that received tumor challenge as compared to unchallenged mice (Fig 2E) .
Interestingly, in Fig. 2B, a strong Our data confirmed that while the tumor center was composed of mainly dead cells, the T cells co-localized at the tumor edge with live tumor cells (Fig. 2F) .
Adoptively transferred T cells responded to experimental metastases
Minimal residual and disseminated metastatic tumors develop at early stages of tumor development and throughout its various stages, which contribute to the high mortality rate of cancer patients 22, 40 . To evaluate whether RT-Rack can detect T-cell response to metastatic lesions, we developed an experimental bioluminescence model mimicking metastasis by injecting Rag -/-mice intravenously with MCA205-TagLuc, a fibrosarcoma derived from the tumor cell line MCA205 by transfection with a plasmid expressing Tag fused to FLuc (TagLuc) 37 . Experimental metastases formed within 4-7 days after tumor cell injection as detected by the FLuc activity from the lungs area (Fig. 3A-B) . The presence of tumor nodules in the lungs was confirmed ex vivo by BLI (Fig. 3E ) and by immunohistochemistry ( Supplementary Fig. S3 ).
Five days following tumor cell injection, R-TCRI T cells were injected and mice were then imaged daily for the detection of T-cell signal. T cells expanded and accumulated in the lung area in tumor-bearing mice whereas no specific signal was detectable from tumor free control mice ( Fig. 3C-F) . Six days after T cell injection, mice were sacrificed and the lungs were imaged ex vivo to confirm the presence of T cells in the tumor-bearing lungs (Fig. 3F) .
T cells, when injected i.v., reach the lungs before continuing to circulate in the blood 41 . To exclude the possibility that the T cell signal measured from the lung was due to an unspecific accumulation in this organ, Rag -/-mice were injected either with MCA205- TagLuc 
3G). This indicates that R-TCRI T cells expansion and accumulation at the site of metastases is antigen specific. Ex vivo imaging of the lungs at the peak of the signal intensity (day 6)
confirmed the presence of R-TCRI T cells only when the cognate antigen was expressed by the tumor cells (Fig. 3H) .
Adoptively transferred T cells responded to autochthonous hepatocellular carcinoma
We have earlier shown that crossing LTL mice with Albumin-Cre (Alb-Cre) mice leads to recombination in the liver and development of hepatocellular carcinoma (HCC) 19 .
Mice transgenic for LTL and Alb-Cre as well as their control littermates (single transgenic or wild type mice) were imaged for FLuc activity to detect leakiness and HCC development. A strong signal could be measured from the liver of the LTL x Alb-Cre double transgenic mouse (Fig. 4A) , indicating HCC development. The leakiness of the stop cassette, resulting in a weak expression of the transgene, could be measured only when the exposure time was increased from 1 second to 1 minute (Fig. 4A ). R-TCRI T cells were injected into these mice and their survival, expansion and accumulation were followed over time by BLI. T cells survived, expanded and preferentially accumulated at the liver site despite the weak expression of TagLuc in several normal tissues (Fig.4B, D) . A weak T cell signal was nevertheless detected in these tissues in both LTL and LTL x Alb-Cre mice (Fig. 4E) .
Imaging FLuc and RLuc signals simultaneously confirmed the co-localization of the signals from tumor and T cells (depicted in orange in Fig. 4C) . Moreover, when injected in mice bearing different tumor burden, T cell accumulation in HCC correlated with tumor burden (Fig. 4 F-H) .
Adoptively transferred TCRI-engineered T cell responded to Tag expressing tumors
So far, we have evaluated the ability of T cells expressing endogenous TCR to expand and home to tumors in various mouse models. Therapeutic T cells can be produced from . T-cell expansion and accumulation were followed in vivo by imaging the mice for RLuc activity. TCRI transduced T cells survived, expanded and accumulated at the tumor site as shown by the strong signals measured 7 and 9 days after T cell injection, whereas no light signal was observed at the tumor site in mice injected with mock-transduced T cells (Fig. 5B-C) . Thus, RT-Rack can be combined with engineered T cells to evaluate T cell response in vivo.
T cells from LTL mice have reduced functional activity and increased expression of PD1
We have analyzed the profile of the T cell response in the tumor-bearing as well as tumor free Fig. S4 ). We found that T cells isolated from tumors or spleens of tumor-bearing Rag -/-mice have the highest effector function (IFN-γ and granzyme B production) and the lowest expression of the inhibitory receptor PD-1 (Fig.   6 ). In contrast, T cells isolated from tumors or spleens of tumor-bearing LTL mice showed the lowest effector function (IFN-γ and granzyme B production) and the highest expression of the inhibitory receptor PD-1 (Fig. 6) .
Discussion
Antigen recognition, expansion, and homing of antigen-specific T cells to tumor sites are the initial steps necessary for the success of adoptive T cell therapy. In this study, we described an approach to detect the response of adoptively transferred T cells over time in vivo. We , but not LTL mice 17, 19 . Therefore, our data show that the limiting step in this model of adoptive T cell therapy is not survival, target antigen recognition, proliferation or homing of the adoptively transferred T cells. Rather, the limiting step is the ability of these cells to differentiate into fully effector T cells that express low level of the inhibitory receptor PD1. Splenocytes from tumor-free littermates were used as control (C, F, I). TILs and splenocytes restimulated with gp33 as negative control did not secrete IFNγ or granzyme B (data not
